Lift Mobile Mindfulness for COVID-19 Distress Symptoms (LIFTCOVID)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This is a randomized clinical trial (RCT) nested within the NIH PETAL Network's COVID cohort study (BLUE CORAL [Biology and Longitudinal Epidemiology: COVID Observational Study]) of patients hospitalized for COVID-19-related illness. COVID-19 patients enrolled in BLUE CORAL with elevated distress symptoms 1 month post-discharge will be randomized to either the Lift mobile app intervention or a usual care control.
Full description
The novel coronavirus (COVID-19) pandemic has changed access to and the delivery of medical care across the world rapidly and radically as increasingly large waves of patients fill clinics, hospital wards, and intensive care units (ICUs). Patients with comparable illnesses have high rates of persistent psychological distress symptoms including depression, anxiety, and PTSD. Currently there are few easily accessible therapies available for this distress in this time of deep fear and worry, social distancing, cancelled clinics, isolation and quarantine practices, and understaffed hospitals.
Lift, a novel mobile app-based mindfulness intervention, may be able to address COVID-19 patients' distress and access to care issues. Lift was piloted successfully in the intensive care unit (ICU; R34 AT00819) and is currently in the midst of a multicenter factorial experimental clinical trial designed to determine which of 8 versions is optimized for symptom relief, cost, and scalability (parent U01 AT009974).
This 2-arm, parallel group randomized clinical trial seeks to expand the scope of the parent U01 project to test the clinical impact of a psychological distress intervention rapidly deployed during a pandemic. This trial will include 300 patients who were hospitalized due to COVID-19; collect data at 1, 3, and 6 months post-discharge; and address 3 specific aims: (1) Compare the clinical impact of Lift vs. usual care control and (2) Compare long-term (6-month) outcomes of RCT patients both by treatment arm as well to the entire BLUE CORAL cohort, and (3) Explore participant-reported barriers and facilitators to intervention deployment, uptake, and engagement in a pandemic.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
BLUE CORAL eligibility (the parent cohort study from which RCT participants will be recruited)
Inclusion criteria:
- Adult hospitalized within 14 days of a positive PCR test for COVID-19
- Evidence of acute COVID-19, with fever or respiratory manifestations, as characterized by signs and symptoms such as cough, dyspnea, tachypnea, hypoxemia, and infiltrates on chest imaging.
Exclusion criteria:
- Lack of informed consent
- More than 72 hours of continuous hospitalization.
- Comfort care orders in place at the time of enrollment and/or unexpected to survive for 24 hours
- Prisoners
- Previous enrollment in BLUE CORAL
LIFT COVID RCT eligibility
Inclusion criteria:
-
Enrolled in BLUE CORAL
-
Survival to time of BLUE CORAL 1-month post-discharge interview
-
English-speaking 3. Domiciled with access to a working telephone and smartphone, tablet, or computer with wifi or internet connection 4. Absence of severe dementia or cognitive dysfunction either before hospitalization or at time of 1 month post-discharge interview
Exclusion criteria:
- PHQ-9 <5 at time of interview 1 month post-discharge
- Suicidal ideation at time of interview 1 month post-discharge
Trial design
Primary purpose
Allocation
Interventional model
Masking
56 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal